Congress Blames Insurance Executives for Rising US Health
The congressional hearing highlighted that US health costs blame insurance practices as a significant factor in the ongoing debate over rising healthcare
Novo obesity drug pricing drops below Lilly’s for U.S. cash
Novo Nordisk's Novo obesity drug pricing reduction for U.S. cash-paying customers could reshape market dynamics and improve treatment affordability amid
Former Novo Nordisk CEO warns Trump drug price policy may
The Trump drug price policy aims to lower U.S. drug costs but may inadvertently restrict access to medicines in Europe, potentially impacting global supply